These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32005117)

  • 21. Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States.
    Pariser AC; Sedghi T; Soulos PR; Killelea B; Gross CP; Mougalian SS
    Breast Cancer Res Treat; 2019 Nov; 178(2):419-426. PubMed ID: 31401686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review.
    Charehbili A; Fontein DB; Kroep JR; Liefers GJ; Mieog JS; Nortier JW; van de Velde CJ
    Cancer Treat Rev; 2014 Feb; 40(1):86-92. PubMed ID: 23891267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. One-Year Neoadjuvant Endocrine Therapy in Breast Cancer.
    Rusz O; Vörös A; Varga Z; Kelemen G; Uhercsák G; Nikolényi A; Ormándi K; Simonka Z; Kahán Z
    Pathol Oncol Res; 2015 Sep; 21(4):977-84. PubMed ID: 25753983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis.
    Tao M; Chen S; Zhang X; Zhou Q
    Medicine (Baltimore); 2017 Dec; 96(51):e9384. PubMed ID: 29390540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant endocrine therapy for resectable breast cancer: A systematic review and meta-analysis.
    Leal F; Liutti VT; Antunes dos Santos VC; Novis de Figueiredo MA; Macedo LT; Rinck Junior JA; Sasse AD
    Breast; 2015 Aug; 24(4):406-12. PubMed ID: 25858103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM; Harhay MO; Zhang P; Ugras S
    Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.
    Iwata H
    Breast Cancer; 2011 Apr; 18(2):92-7. PubMed ID: 21140250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.
    Chia YH; Ellis MJ; Ma CX
    Br J Cancer; 2010 Sep; 103(6):759-64. PubMed ID: 20700118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fulvestrant for hormone-sensitive metastatic breast cancer.
    Lee CI; Goodwin A; Wilcken N
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011093. PubMed ID: 28043088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR-Positive Breast Cancer.
    Wang W; Liu C; Zhou W; Xia T; Xie H; Wang S
    Sci Rep; 2016 May; 6():25615. PubMed ID: 27174543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of concomitant chemo-endocrine therapy in neoadjuvant treatment of hormone-positive HER2-negative breast cancer: a systemic review and meta-analysis.
    Ergun Y; Ucar G; Akagündüz B
    Expert Opin Drug Saf; 2023 Apr; 22(4):313-322. PubMed ID: 37057733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment.
    Li JJ; Shao ZM
    Chin Clin Oncol; 2016 Jun; 5(3):40. PubMed ID: 27164856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.